

## Original Article

# Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease

Tilman Humpl,<sup>1</sup> Janette T. Reyes,<sup>1</sup> Simon Erickson,<sup>2</sup> Ruth Armano,<sup>3</sup> Helen Holtby,<sup>1</sup> Ian Adatia<sup>4</sup>

<sup>1</sup>Hospital for Sick Children, University of Toronto, Toronto, Canada; <sup>2</sup>Princess Margaret Hospital, University of Western Australia, Perth, Australia; <sup>3</sup>Cliniques Universitaires de St Luc, Brussels, Belgium; <sup>4</sup>Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada

**Abstract Objectives:** We hypothesised that sildenafil would improve hemodynamics in children with pulmonary hypertension and attenuate rebound pulmonary hypertension after inhaled nitric oxide withdrawal. *Patients and methods:* We undertook an open-label, single-drug study of sildenafil in patients under 5 years of age with either symptomatic or rebound pulmonary hypertension following inhaled nitric oxide withdrawal. *Results:* We recruited 25 patients (median age 180 days, 10–1790) to receive sildenafil. The median right ventricular to systemic systolic blood pressure ratio before sildenafil therapy was 1.0 (0.5–1.4) and decreased to 0.5 (with a range from 0.3 to 1.3;  $p = 0.0002$ ). In five patients the baseline pulmonary vascular resistance index was 10 (7.1–13.6) Wood units metre square and decreased to 5.8 (2.7–15.6) Wood units metre square ( $p = 0.04$ ) at 6 months. Ten patients were treated with sildenafil for a median of 34 days (9–499) until resolution of pulmonary artery hypertension and continue to do well. Six patients continued sildenafil therapy for a median of 1002 days (384–1574) with improvement but without resolution of pulmonary hypertension. There was no change in serum creatinine, urea, liver function tests, or platelet count. In 15 patients sildenafil abolished rebound pulmonary artery hypertension following withdrawal of inhaled nitric oxide. Median right ventricular pressure to systemic systolic pressure ratio decreased from 1.0 (0.8–1.4) during nitric oxide withdrawal to 0.4 (0.3–0.8)  $p = 0.006$  after pre-treatment with sildenafil. *Conclusion:* In children under 5 years of age with severe pulmonary hypertension, sildenafil therapy resulted in prolonged hemodynamic improvements without adverse effects. Sildenafil attenuated rebound pulmonary hypertension after withdrawal of inhaled nitric oxide.

Keywords: Sildenafil; neonatal; pulmonary hypertension; congenital cardiac disease; congenital diaphragmatic hernia

Received: 3 July 2010; Accepted: 31 October 2010; First published online: 8 December 2010

**P**ULMONARY ARTERIAL HYPERTENSION IN NEONATES and young children often has heterogeneous causes compared with adults and older children. However, untreated, the mortality and morbidity are as grave as pulmonary vascular disease in older patients.<sup>1</sup> Infants with bronchopulmonary dysplasia have a poor outcome if they develop pulmonary hypertension, and there is a clear need for therapy in this group of patients.<sup>2</sup> Children

with congenital cardiac disease may continue to suffer from pulmonary vascular disease after surgical repair. The advent of newer therapies for pulmonary hypertension that may be administered orally have obvious appeal in the management of neonatal and childhood pulmonary hypertensive vascular disease. Sildenafil is a highly selective and potent inhibitor of the cyclic guanosine monophosphate specific type 5 phosphodiesterase isoenzyme.<sup>3</sup> Oral sildenafil improves symptoms and exercise capacity and decreases pulmonary vascular resistance in adults and older children with pulmonary arterial hypertension.<sup>4–6</sup> There are few reports of the effects of prolonged sildenafil therapy in neonates, infants,

Correspondence to: Dr I. Adatia, Room 3A1.44, Walter C Mackenzie Health Sciences Center, 8440 112 Street, Edmonton, Alberta T6G 3T7, Canada. Tel: 780 407 3642; Fax: 780 407 3954 E-mails: iadatia@ualberta.ca, ianadatia@me.com

and children under 5 years of age.<sup>7</sup> Acute administration of sildenafil in neonates and children is tolerated well, reduces pulmonary artery pressures, and improves oxygenation in persistent pulmonary hypertension of the newborn.<sup>8–11</sup> Inhaled nitric oxide, which activates cyclic guanosine monophosphate, is an effective pulmonary vasodilator in a variety of neonatal and childhood pulmonary vascular diseases. We hypothesised that sildenafil would be beneficial in young children with pulmonary arterial hypertension. Therefore, we investigated prospectively the effects of oral sildenafil therapy in neonates, infants, and children under 5 years of age diagnosed with pulmonary hypertensive vascular disease.

## Materials and methods

The study protocol was approved by the research and ethics review board of the Hospital for Sick Children, Toronto, Canada and informed signed consent was obtained from the patients' parents.

We undertook an open-label, single-drug clinical study of sildenafil for the treatment of pulmonary hypertension in neonates, infants, and children under 5 years of age.

Eligible patients for study were under 5 years of age and diagnosed with pulmonary arterial hypertension. We defined pulmonary arterial hypertension as a mean pulmonary artery pressure greater than 25 millimetres of mercury or right ventricular systolic pressure of greater than 40 millimetres of mercury or pulmonary vascular resistance index greater than 3 Wood units metre square.<sup>12,13</sup> There were two criteria for entry into the study: either the patients received inhaled nitric oxide therapy in the critical care unit and suffered from symptomatic rebound pulmonary hypertension, or they were diagnosed with pulmonary hypertensive vascular disease by cardiac catheterisation. Patients with surgically correctable pulmonary arterial hypertension secondary to congenital cardiac disease were excluded. However, patients with congenital cardiac disease who had sustained elevation of pulmonary artery pressures despite surgical correction, or who were not candidates for surgery, were eligible for inclusion.

### *Patients with rebound pulmonary arterial hypertension after nitric oxide withdrawal*

Patients were eligible to receive sildenafil if rebound pulmonary arterial hypertension occurred after withdrawal of inhaled nitric oxide, despite following the weaning protocol described below, and resolved with reinstitution of inhaled nitric oxide.

Inhaled nitric oxide was decreased gradually from 20 to 5 parts per million by 5 parts per million per hour and then by 1 part per million per hour. While

weaning the dose of nitric oxide, the arterial pH was maintained above 7.35. If arterial oxygen saturation decreased below 95% or 5% from baseline we increased the FiO<sub>2</sub>. Rebound pulmonary arterial hypertension on withdrawal of inhaled nitric oxide was defined by a 15% increase in right ventricular to systemic systolic pressure ratio unresponsive to increasing the FiO<sub>2</sub> with a normal pH. Right ventricular pressure was measured by echocardiography. Patients without tricuspid or pulmonary regurgitation were excluded from analysis. Rebound pulmonary arterial hypertension was treated with nitric oxide 5 parts per million and oral sildenafil administered every 6 hours. Nitric oxide withdrawal was re-attempted within 24 hours. Sildenafil was continued until pulmonary arterial hypertension resolved.

### *Patients with sustained pulmonary arterial hypertension*

Patients with sustained symptomatic pulmonary artery hypertension as defined above were eligible for sildenafil therapy after assessment by history, physical examination, echocardiography, ECG, and chest X-ray, and if clinically indicated by high-resolution chest computed tomography scan, nuclear ventilation-perfusion scan and a cardiac catheterisation.

All patients were followed clinically and by echocardiography for the duration of treatment. Right ventricular systolic pressures were estimated by echocardiography and calculated by measuring the velocity of the tricuspid valve regurgitant jet using the modified Bernoulli equation ( $4 \times$  squared velocity of tricuspid valve regurgitant jet) without estimation of right atrial pressure. The ratio of right ventricular systolic pressure divided by systemic blood pressure was calculated for each echocardiographic examination. Systemic blood pressure was measured by cuff, unless the patient had an indwelling arterial line. Ten patients underwent cardiac catheterisation before starting sildenafil therapy. Five patients underwent follow-up cardiac catheterisation. Cardiac catheterisation was performed under general anaesthesia with mechanical ventilation with a baseline FiO<sub>2</sub> 0.25. Anaesthesia was induced with sevoflurane, midazolam, and remifentanyl. Sevoflurane was discontinued after induction. Rocuronium was used for muscle relaxation. We recorded heart rate, systemic and pulmonary arterial pressure, and left atrial pressure (or pulmonary capillary wedge pressure) and right atrial pressure in the standard manner with fluid-filled catheters. Oxygen consumption was measured. Oxygen saturations were measured by co-oximetry after sampling in the superior caval vein, pulmonary vein, pulmonary artery, and systemic artery. We estimated systemic and

Table 1. Patient details categorised as neonates (numbers 1–5), idiopathic pulmonary arterial hypertension (numbers 6–8), secondary pulmonary arterial hypertension not associated with congenital cardiac disease (numbers 9 and 10), pulmonary arterial hypertension associated with congenital cardiac disease (numbers 11–25).

Patient	Gender	Diagnosis	Age	Duration of therapy (days)	Outcome
1	F	CDH	10 days	35*	Alive
2	F	CDH	15 days	56*	Alive
3	M	CDH	16 days	12**	Dead
4	F	CDH	31 days	159**	Dead
5	F	PPHN	13 days	12*	Alive
6	M	IPAH	1 year 4 months	532**	Dead
7	F	IPAH	1 year 7 months	1345**	Dead
8	F	IPAH	4 years 11 months	384***	Alive
9	M	ALL post-chemoRx PVOD	2 years 7 months	792**	Dead
10	M	BPD/PE	2 years 7 months	81**	Dead
11	M	s/p valvuloplasty MS, AS, AI	3 months	1330***	Alive
12	F	MS, CoA s/p repair	4 months	33*	Alive
13	F	s/p repair AVSD, tri 21	5 months	9*	Alive
14	M	s/p repair PVS, ASD	5 months	31*	Alive
15	F	s/p repair VSD, tracheal stenosis, VACTERL	5 months	24*	Dead
16	F	s/p repair AVSD	6 months	206*	Alive
17	M	s/p repair VSD, omhalocele	6 months	499*	Alive
18	M	s/p repair PVS, VSD, ASD	6 months	119**	Dead
19	M	VSD	7 months	82*	Alive
20	M	Hepatopulmonary fusion with scimitar syndrome	7 months	21**	Dead
21	F	s/p repair ASD, VSD, Tri 16	10 months	674***	Alive
22	F	s/p repair VSD, PDA, Tri 21	1 year 6 months	594***	Alive
23	F	LAI, interrupted IVC with azygous continuation	2 years 5 months	1574***	Alive
24	M	s/p repair PVS, ASD, PDA, VSD,	2 years 7 months	24*	Alive
25	F	ASD****	3 years 5 months	1549***	Alive

ALL post-chemoRx = acute lymphatic leukaemia post-chemotherapy; AI = aortic incompetence; AS = aortic stenosis; ASD = atrial septal defect; AVSD = atrioventricular septal defect; BPD = bronchopulmonary dysplasia; CDH = congenital diaphragmatic hernia; CoA = aortic coarctation; IPAH = idiopathic pulmonary arterial hypertension; IVC = inferior caval vein; LAI = left atrial isomerism; MS = mitral stenosis; PDA = patent arterial duct; PE = multiple pulmonary emboli; PPHN = persistent pulmonary hypertension of the newborn; PVOD = pulmonary veno-occlusive disease; PVS = pulmonary vein stenosis; SPH = secondary pulmonary arterial hypertension; Tri = trisomy; VSD = ventricular septal defect

\*Discontinued sildenafil with resolution of pulmonary arterial hypertension

\*\*Death on therapy

\*\*\*Maintained on sildenafil

\*\*\*\*Failed attempted ASD closure with suprasystemic pulmonary artery pressures, lung biopsy Grade 111 by Heath-Edwards

pulmonary blood flow from the Fick equation and calculated systemic and pulmonary vascular resistance from standard equations (mean arterial pressure minus mean atrial pressure divided by flow). Blood flow and vascular resistances were indexed to body surface area.

*Preparation and dosing of sildenafil:* Sildenafil was administered either by nasogastric tube or orally after crushing and dissolving the tablets. We administered 0.25 milligram per kilogram per dose and increased this to 1 milligram per kilogram per dose administered four times daily as tolerated and by observation of clinical effect.

#### Statistical analysis

Non-normally distributed data are presented as median with a range. We compared paired variables before and after sildenafil therapy by paired non-parametric tests.

## Results

Between November 2000 and January 2005 a total of 25 patients at a median age of 180 days (10–1790 days) were recruited and received oral sildenafil therapy. The patient details are summarised in Table 1.

### Patients with sustained pulmonary arterial hypertension

We started sildenafil at a dose of 0.25 milligram per kilogram, and in the absence of unwanted side effects increased this to approximately 1.0 milligrams per kilogram. The median dose administered was 0.7 milligram per kilogram (0.5–2.25) four times daily.

The median duration of therapy for patients whose pulmonary artery pressures decreased to near-normal levels and in whom sildenafil was discontinued (n = 11) was 34 days (9–499).

Table 2. Echocardiographic estimation of right ventricular systolic pressure (\*RVSP) in different subgroups of children with pulmonary hypertension

	RVSP/SBP ratio before treatment	RVSP/SBP ratio at last available echocardiographic study	p-value
CDH/PPHN	1.0 (0.8–1.4)	0.4 (0.3–0.8)	0.006
IPAH	1.0 (0.9–1.4)	1.2 (0.9–1.3)	0.44
CHD	1.0 (0.5–1.4)	0.5 (0.3–1.2)	0.001
All patients	1.0 (0.5–1.4)	0.5 (0.3–1.3)	0.0002

CDH = congenital diaphragmatic hernia; CHD = repaired congenital cardiac disease; PPHN = persistent pulmonary hypertension of the newborn; IPAH = idiopathic pulmonary arterial hypertension; SPH = non-CHD secondary pulmonary arterial hypertension; RVSP = right ventricular systolic pressure; SBP = systemic systolic blood pressure

\*RVSP measured from velocity of tricuspid valve regurgitation in all patients

### Echocardiography data

The median ratio of the right ventricular systolic pressure divided by systemic blood pressure for all patients at the initiation of sildenafil therapy was 1.0 (0.5–1.4) and decreased to 0.5 (0.3–1.3) at the last echocardiography study. This change was statistically significant ( $p = 0.0002$ ; Table 2).

### Cardiac catheterisation

Ten patients underwent a cardiac catheterisation before the initiation of sildenafil therapy. The median pulmonary vascular resistance index was 12.9 (7.1–23) Wood units metre square. Five patients underwent a follow-up study after a median time of 6 months (83–637 days) from the start of sildenafil. The median pulmonary vascular resistance index in these five patients at the initiation of sildenafil therapy was 10 (7.1–13.6) Wood units metre square and decreased to 5.8 (2.7–15.6) Wood units metre square ( $p = 0.04$ ) at follow-up cardiac catheterisation.

### Deaths

Nine patients in the cohort died after a median of 119 days (12–1345). Eight of nine patients died while still receiving sildenafil. None of the deaths were attributable to sildenafil therapy. Three patients (numbers 3, 4, and 20 in Table 1) with lung hypoplasia died. One patient (number 20) with congenital hepatopulmonary fusion (diagnosed as congenital diaphragmatic hernia before autopsy), severe right lung hypoplasia, and anomalous pulmonary venous drainage to the inferior caval vein died receiving compassionate care after a prolonged course (including tracheostomy and multiple attempts to wean the ventilator) in the critical care unit. Serial MRI scans demonstrated growth of the proximal hypoplastic pulmonary artery, and cardiac catheterisation demonstrated a decrease in pulmonary vascular resistance index during sildenafil therapy. The findings were confirmed at autopsy. Two patients (numbers 3 and 4) with congenital diaphragmatic hernia and severe

pulmonary hypoplasia died after 12 and 159 days, respectively. Both patients received sildenafil to facilitate the discontinuation of nitric oxide and responded with a decrease in right ventricular pressure. We continued treatment with sildenafil because the right ventricular pressures remained elevated and we were unable to wean support from mechanical ventilation.

Three ex-premature infants died after prolonged hospital courses. One of these (number 10) had severe bronchopulmonary dysplasia and multiple pulmonary emboli with almost complete occlusion of the left pulmonary artery. The pulmonary emboli originated from a tricuspid valve vegetation secondary to a central line infection. The findings were confirmed at autopsy. The second (number 18) had congenital pulmonary vein stenosis and underwent repair of the pulmonary veins by sutureless repair. The pulmonary hypertension resolved with sildenafil therapy from suprasystemic to half-systemic levels. However, 3 months after hospital discharge the child presented to an outside hospital moribund with fever and respiratory distress. Autopsy demonstrated unobstructed pulmonary veins and grade 1 pulmonary artery changes. The cause of death was overwhelming respiratory syncytial viral infection. The other ex-preterm infant (number 15) died late after a repaired ventricular septal defect as a sequelae of multiple congenital malformations. The pulmonary hypertension had resolved on sildenafil and the drug was discontinued before death.

Patient number 6 with idiopathic pulmonary arterial hypertension deteriorated on sildenafil. Intravenous prostacyclin therapy was added to sildenafil therapy. However, the patient died with an overwhelming respiratory syncytial viral infection. Autopsy demonstrated severe pulmonary hypertensive vasculopathy.

Patient number 7 with idiopathic pulmonary artery hypertension died after more than 3 years of therapy with sildenafil. The patient had been started initially on intravenous prostacyclin therapy but experienced syncope. A static balloon dilation of

Table 3.

	Baseline median (range)	Follow up median (range)
Creatinine ( $\mu\text{mol/l}$ )	30 (17–74)	36 (18–67)
Urea ( $\mu\text{mol/l}$ )	4.5 (2.1–9.8)	5.5 (1–15.2)
Total protein (g/l)	33 (16–44)	36 (19–47)
Albumin (units/l)	128 (67–512)	174 (134–255)
Alkaline phosphatase ( $\mu\text{mol/l}$ )	6 (1–22)	6 (0–8)
Unconjugated bilirubin (units/l)	874 (498–1686)	734 (496–893)
Lactate dehydrogenase (units/l)	26 (3–92)	18 (3–70)
Alanine aminotransferase (units/l)	26 (22–89)	43 (16–61)
Aspartate aminotransferase (units/l)	45 (22–89)	43 (16–61)
Gamma-glutamic transpeptidase (units/l)	45 (12–84)	29 (12–100)
Platelet count ( $10^9/\text{l}$ )	280 (57–549)	300 (45–681)

the atrial septum was performed, and sildenafil and then bosentan therapy were started. No further syncopal episodes occurred. Subsequently, the intravenous prostacyclin was weaned and discontinued, at parental request, with only mild increase in pulmonary vascular resistance index. One year later the child presented with seizures and autopsy demonstrated acute encephalitis as the cause of death. Pulmonary vascular histology showed severe idiopathic pulmonary arteriopathy.

Patient number 9 developed pulmonary hypertension after chemotherapy for leukaemia. He responded to sildenafil with a decrease in mean pulmonary artery pressure by 10 millimetres of mercury during cardiac catheterisation (40–30 millimetres of mercury). He failed a challenge with calcium channel blocker therapy. He had elevated liver function tests excluding him from bosentan therapy. He was started on sildenafil therapy. Cardiac catheterisation 6 months later measured a mean pulmonary artery pressure of 52 millimetres of mercury. The family declined intravenous prostacyclin therapy. Two years after diagnosis the child was admitted with worsening respiratory function and fluid retention, leading to multi-organ failure. Autopsy demonstrated pulmonary veno-occlusive disease, secondary to chemotherapy.

Thus, three patients died with severe lung hypoplasia. Four patients died from causes unrelated to the pulmonary vascular disease. One patient died from post-chemotherapy pulmonary veno-occlusive disease. One patient with severe bronchopulmonary dysplasia and multiple pulmonary emboli died.

#### *Biochemistry and platelet counts*

No major side effects attributable to sildenafil were reported by parents or children. There was no change in serum creatinine, urea, liver function tests, or platelet count ( $p > 0.08$ ; Table 3).

#### *Patients with rebound pulmonary hypertension after nitric oxide withdrawal*

Fifteen out of 36 patients who received inhaled nitric oxide during the study period suffered from rebound pulmonary arterial hypertension as defined above. Following reinstatement of nitric oxide these 15 patients received sildenafil to facilitate subsequent withdrawal of nitric oxide. Sildenafil was administered by nasogastric tube at a dose of 0.25 milligram per kilogram, and if tolerated the dose was increased incrementally to 1.0 milligram per kilogram and given every 6 hours. We discontinued nitric oxide after the second dose of sildenafil. Following sildenafil treatment, we discontinued nitric oxide therapy, without rebound pulmonary arterial hypertension, in all 15 patients. The median ratio of right ventricular systolic pressure to systemic systolic pressure was 1.0 (0.8–1.4) during rebound and 0.4 (0.3–0.8) following nitric oxide withdrawal after sildenafil treatment  $p = 0.006$ .

#### **Discussion**

We found that prolonged oral sildenafil was tolerated well and improved pulmonary vascular haemodynamics in children less than 5 years of age with sustained pulmonary arterial hypertension. In addition, oral sildenafil effectively prevented rebound pulmonary hypertension after withdrawal of inhaled nitric oxide therapy.

The long-term evaluation of the effects of treatment in children under 5 years of age with pulmonary hypertensive vascular disease is difficult. Most studies of adults and older children have used the results of cardiopulmonary exercise testing and the distance walked in 6 minutes as indicators of improvement or deterioration. These tests are clearly not applicable in very young children and infants. In general, we lack surrogates of exercise

tolerance and capacity in very young children.<sup>14</sup> This partly accounts for the under-representation of children under 12 years of age in pulmonary hypertension drug trials. Therefore, we chose to follow the children with echocardiography and, when appropriate, cardiac catheterisation. This approach is not without precedent. Improvement in echocardiographic estimation of right ventricular pressure has been reported in children under 2 years of age with pulmonary hypertension due to chronic lung disease treated with sildenafil.<sup>7</sup> The present study confirms the safety and efficacy demonstrated by Mourani et al.<sup>7</sup> and broadens the diagnostic categories of responders to therapy. The clinical and echocardiographic improvements were confirmed in five patients by cardiac catheterisation, which demonstrated a 55% reduction in pulmonary vascular resistance index at follow-up.

Nine patients died during the study period, and this emphasises the vulnerability of young children with pulmonary hypertension. However, of the eight out of nine who died while receiving sildenafil therapy, four died from the direct sequelae of their pulmonary vascular disease, and this is similar to the mortality reported by Mourani et al.<sup>7</sup> Two of the four patients died from severe lung hypoplasia and one from a combination of severe bronchopulmonary dysplasia and additional loss of pulmonary vascular cross-sectional area from pulmonary emboli. This emphasises the high mortality of pulmonary hypertension associated with severe lung hypoplasia as reported by Mourani.<sup>7</sup> A further death occurred from pulmonary veno-occlusive disease, a known, albeit rare, complication of chemotherapy.<sup>15</sup> Pulmonary veno-occlusive disease is notoriously difficult to diagnose pre-mortem and in general refractory to medical therapy.<sup>15</sup>

### *Rebound pulmonary hypertension*

Rebound pulmonary hypertension may be a difficult, even life-threatening, clinical problem that delays tracheal extubation in patients with pulmonary hypertension.<sup>16,17</sup> In our study, we found that approximately 60% of young infants treated with inhaled nitric oxide and weaned according to our protocol will have rebound pulmonary hypertension as defined above. Our definition of rebound pulmonary hypertension was deliberately inclusive, and this overestimated the number of patients that need treatment on clinical grounds. Sildenafil obviated rebound pulmonary hypertension in all 15 patients and reduced right ventricular to systemic pressure ratio below 50% in most patients. These findings are in keeping with those of Namachivayam et al.<sup>18</sup>

### *Adverse events*

Sildenafil treatment did not affect biochemical parameters of renal or hepatic function, in keeping with findings in older children.<sup>4</sup> This may be an advantage of sildenafil over endothelin receptor antagonists, which require monthly monitoring of liver function tests. Although sildenafil may affect platelet function, bleeding complications were not encountered and platelet counts remained stable. Retinal side effects of sildenafil have been reported. However, a recent comprehensive assessment of retinal function after 6 months of sildenafil and tadalafil therapy found no differences compared with placebo.<sup>19</sup> In a previous study in older children no changes in colour vision were detected during sildenafil therapy.<sup>4</sup> Adverse events may have been under-reported, particularly oesophageal reflux and dysmotility.<sup>20</sup> Feeding intolerance is a common accompaniment of chronically ill children. However, in general enteral tolerance of feeds improved on sildenafil therapy in our study.

The limitations of this study are the absence of a control group. Therefore, improvements may not have been due to sildenafil therapy only. The patients were followed and managed in a dedicated childhood pulmonary hypertension clinic, which may contribute to improved outcomes.<sup>14</sup>

Adverse events such as oesophageal reflux may have been under-detected as discussed above, and would require careful evaluation in a future trial.

The use of echocardiographic outcome parameters is not ideal, but the options are limited in this age group. In routine clinical practice, echocardiography is used to follow and aid decision making in young patients. Thus, our study reflects daily practice.

In conclusion, we found that in children under 5 years of age with pulmonary hypertensive vascular disease, prolonged enteral therapy with sildenafil resulted in hemodynamic improvements as assessed by echocardiography and cardiac catheterisation. There were no adverse effects on biochemical indicators of liver, haematological, or renal function. In addition, enterally administered sildenafil obviated rebound pulmonary hypertension after withdrawal of inhaled NO and facilitated weaning of ventilator support. Further evaluation of sildenafil therapy for chronic childhood pulmonary hypertensive vascular disease in prospective controlled trials may be indicated.

### **Acknowledgements**

The authors gratefully acknowledge the support of the staff in the echocardiography laboratory, the cardiac catheterisation laboratory and the pharmacy at the Hospital for Sick Children, Toronto.

## References

1. Adatia I. Recent advances in pulmonary vascular disease. *Curr Opin Pediatr* 2002; 14: 292–297.
2. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. *Pediatrics* 2007; 120: 1260–1269.
3. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43: 68S–72S.
4. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. *Circulation* 2005; 111: 3274–3280.
5. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. *J Am Coll Cardiol* 2004; 43: 1149–1153.
6. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation* 2003; 108: 2066–2069.
7. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. *J Pediatr* 2009; 154: 379–384.
8. Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. *J Pediatr* 2009; 155: 841–847; e841.
9. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. *Circulation* 2003; 108 Suppl 1: II167–II173.
10. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. *Intensive Care Med* 2003; 29: 1996–2003.
11. Noori S, Friedlich P, Wong P, Garingo A, Seri I. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. *Neonatology* 2007; 91: 92–100.
12. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *Eur Heart J* 2004; 25: 2243–2278.
13. Grunig E, Weissmann S, Ehlken N, et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. *Circulation* 2009; 119: 1747–1757.
14. Adatia I. Improving the outcome of childhood pulmonary arterial hypertension: the effect of bosentan in the setting of a dedicated pulmonary hypertension clinic. *J Am Coll Cardiol* 2005; 46: 705–706.
15. Adatia I. Pulmonary veno-occlusive disease. In: Freedom RM, Yoo S-J, Mikailian H and Williams WG (eds). *The Natural and Modified History of Congenital Heart Disease*. Futura, New York, 2004; 513.
16. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. *Ann Thorac Surg* 1996; 62: 1759–1764.
17. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. *Lancet* 1995; 346: 51–52.
18. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. *Am J Respir Crit Care Med* 2006; 174: 1042–1047.
19. Cordell WH, Maturi RK, Costigan TM, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. *Arch Ophthalmol* 2009; 127: 367–373.
20. Keller RL, Moore P, Teitel D, Hawgood S, McQuitty J, Fineman JR. Abnormal vascular tone in infants and children with lung hypoplasia: findings from cardiac catheterization and the response to chronic therapy. *Pediatr Crit Care Med* 2006; 7: 589–594.